{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:30:05Z","timestamp":1792445405848,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Management of the node-positive axilla after neoadjuvant chemotherapy is controversial. The aim of this study is to predict the group of patients who may require a less invasive approach for axillary management. One possible group are patients with pathological complete response of the primary after chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A unicentral retrospective cohort study including all breast cancer patients with axillary node metastases at presentation who received neoadjuvant chemotherapy resulting in pathological complete response. Pathological complete response in the axillary lymph nodes was recorded. A correlation between the response in the primary tumour and the lymph nodes was assessed. A subgroup analysis was conducted for different biological groups.<\/jats:p>\n                <jats:p>Complete response was seen in the axillary nodes in 80.5% of patients. Patients with lobular cancer were less likely to show a similar response in the axilla as the primary tumour (<jats:italic>p<\/jats:italic> = 0.077). A higher incidence of axillary response was observed in HER2-positive tumours (<jats:italic>p<\/jats:italic> = 0.082). All patients with grade 3 tumours achieved complete response in the axilla (<jats:italic>p<\/jats:italic> = 0.094). Patients with negative or weak positive hormone receptor status had a significantly higher rate of complete response in the axilla compared to strongly positive hormone receptor status (OR, 7.8; 95% CI, 1.7\u201334.5; <jats:italic>p<\/jats:italic> = 0.007).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A less invasive axillary surgery may be safely recommended in selected group of node-positive patients after neoadjuvant chemotherapy when the primary tumour shows complete response. This group may include HER2-positive, ER-negative and grade 3 tumours. Less response is expected in ER-positive and lobular carcinoma even with complete response in the primary.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43046-021-00061-9","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T22:48:23Z","timestamp":1612824503000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The implications of a pathological complete response of the primary tumour after neoadjuvant chemotherapy for breast cancer on axillary surgery"],"prefix":"10.1186","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6807-313X","authenticated-orcid":false,"given":"Mina M. G.","family":"Youssef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Metwally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer M.","family":"Manie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"key":"61_CR1","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.breast.2014.06.004","volume":"23","author":"M Untch","year":"2014","unstructured":"Untch M, Konecny GE, Paepke S, et al. Current and future role of neoadjuvant therapy for breast cancer. The Breast. 2014;23:526\u201337.","journal-title":"The Breast"},{"issue":"8","key":"61_CR2","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/annonc\/mdx308","volume":"28","author":"G Curigliano","year":"2017","unstructured":"Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28(8):1700\u201312.","journal-title":"Ann Oncol"},{"key":"61_CR3","doi-asserted-by":"publisher","first-page":"abstract 1007","DOI":"10.1200\/jco.2015.33.15_suppl.1007","volume":"33","author":"M Golshan","year":"2015","unstructured":"Golshan M, Cirrincione CT, Carey LA, et al. Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: combined results of CALGB 40603 and 40601 (Alliance). J Clin Oncol. 2015;33:abstract 1007.","journal-title":"J Clin Oncol"},{"key":"61_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/jncimonographs\/lgv004","volume":"2015","author":"DF Hayes","year":"2015","unstructured":"Hayes DF, Schott AF. Neoadjuvant chemotherapy: what are the benefits for the patient and for the investigator? JNCI Monogr. 2015;2015:36\u20139.","journal-title":"JNCI Monogr"},{"key":"61_CR5","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.clon.2017.06.003","volume":"29","author":"H Cain","year":"2017","unstructured":"Cain H, Macpherson IR, Beresford M, et al. Neoadjuvant therapy in ear breast cancer: treatment considerations and common debates in practice. Clin Oncol. 2017;29:642\u201352.","journal-title":"Clin Oncol"},{"key":"61_CR6","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","volume":"26","author":"P Rastogi","year":"2008","unstructured":"Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project protocols B-18 and B-27. J Clin Oncol. 2008;26:778\u201385.","journal-title":"J Clin Oncol."},{"key":"61_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","volume":"19","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2018","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19:27\u201339.","journal-title":"Lancet Oncol"},{"key":"61_CR8","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1245\/s10434-015-4404-8","volume":"22","author":"P Cortazar","year":"2015","unstructured":"Cortazar P, Geyer CE Jr. Pathological complete response in neoadjuvant treatment of breast cancer. Ann Surg Oncol. 2015;22:1441\u20136.","journal-title":"Ann Surg Oncol"},{"issue":"15","key":"61_CR9","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G Von Minckwitz","year":"2012","unstructured":"Von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796\u2013804.","journal-title":"J Clin Oncol."},{"issue":"11","key":"61_CR10","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1245\/s10434-016-5246-8","volume":"23","author":"A Mamtani","year":"2016","unstructured":"Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol. 2016;23(11):3467\u201374.","journal-title":"Ann Surg Oncol"},{"key":"61_CR11","unstructured":"Riogi B, Sripadam R, Barker D, et al. Management of the axilla following neoadjuvant chemotherapy for breast cancer- a change in practice. Surgeon. 2020; S1479-666X(20)30020-2."},{"key":"61_CR12","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1200\/JCO.2013.54.1177","volume":"32","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Temin S, Edge SB, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014;32:1365\u201383.","journal-title":"J Clin Oncol."},{"key":"61_CR13","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1245\/s10434-012-2484-2","volume":"19","author":"R Alvarado","year":"2012","unstructured":"Alvarado R, Yi M, Le-Petross H, et al. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol. 2012;19:3177\u201384.","journal-title":"Ann Surg Oncol."},{"key":"61_CR14","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455\u201361.","journal-title":"JAMA."},{"key":"61_CR15","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609\u201318.","journal-title":"Lancet Oncol"},{"issue":"3","key":"61_CR16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258\u201364.","journal-title":"J Clin Oncol."},{"key":"61_CR17","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.clon.2019.05.021","volume":"31","author":"A Gandhi","year":"2019","unstructured":"Gandhi A, Coles C, Makris A, et al. Axillary surgery following neoadjuvant chemotherapy \u2013 multidisciplinary guidance from the Association of Breast Surgery, Faculty of Clinical Oncology of the Royal College of Radiologists, UK Breast Cancer Group, National Coordinating Committee for Breast Pathology and British Society of Breast Radiology. Clin Oncol. 2019;31:664\u20138.","journal-title":"Clin Oncol"},{"issue":"12","key":"61_CR18","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1001\/jamasurg.2018.2696","volume":"153","author":"AU Barron","year":"2018","unstructured":"Barron AU, Hoskin TL, Day CN, et al. Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy. JAMA Surg. 2018;153(12):1120\u20136.","journal-title":"JAMA Surg"},{"issue":"3","key":"61_CR19","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/SLA.0000000000003126","volume":"271","author":"S Samiei","year":"2020","unstructured":"S Samiei, , T van Nijnatten, L de Munck, et al. Correlation between pathologic complete response in the breast and absence of axillary lymph node metastases after neoadjuvant systemic therapy. Ann Surg 2020;271(3):574-580.","journal-title":"Ann Surg"},{"issue":"5","key":"61_CR20","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0960-9776(03)00106-1","volume":"12","author":"KN Ogston","year":"2003","unstructured":"Ogston KN, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12(5):320\u20137.","journal-title":"Breast"},{"issue":"5","key":"61_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.clbc.2013.12.015","volume":"14","author":"R Jan Schipper","year":"2014","unstructured":"Jan Schipper R, Moossdorff M, Nelemans PJ, et al. A model to predict pathologic complete response of axillary lymph nodes to neoadjuvant chemo(immuno)therapy in patients with clinically node-positive breast cancer. Clin Breast Cancer. 2014;14(5):315\u201322.","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"61_CR22","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/SLA.0000000000002953","volume":"268","author":"OM Fayanju","year":"2018","unstructured":"Fayanju OM, Ren Y, Thomas SM, et al. The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB). Ann Surg. 2018;268(4):591\u2013601.","journal-title":"Ann Surg."},{"key":"61_CR23","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.ejso.2019.11.498","volume":"46","author":"C Morgan","year":"2020","unstructured":"Morgan C, Stringfellow TD, Rolph R, et al. Neoadjuvant chemotherapy in patients with breast cancer: does response in the breast predict axillary node response? Eur J Surg Oncol. 2020;46:522\u20136.","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"61_CR24","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamasurg.2017.0562","volume":"152","author":"AB Tadros","year":"2017","unstructured":"Tadros AB, Yang WT, Krishnamurthy S, et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg. 2017;152(7):665\u201370.","journal-title":"JAMA Surg"},{"key":"61_CR25","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1016\/j.ejca.2012.05.023","volume":"48","author":"N Houssami","year":"2012","unstructured":"Houssami N, Macaskill P, von Minckwitz G, et al. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012;48:3342\u201354.","journal-title":"Eur J Cancer."},{"key":"61_CR26","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164\u201372.","journal-title":"Lancet."},{"issue":"43","key":"61_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001720","volume":"94","author":"JY Kim","year":"2015","unstructured":"Kim JY, Park HS, Kim S, et al. Prognostic nomogram for prediction of axillary pathologic complete response after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer. Medicine (Baltimore). 2015;94(43):e1720.","journal-title":"Medicine (Baltimore)"},{"key":"61_CR28","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s10549-015-3280-z","volume":"149","author":"Y Feng","year":"2015","unstructured":"Feng Y, Huang R, He Y, et al. Efficacy of physical examination, ultrasound, and ultrasound combined with fine-needle aspiration for axilla staging of primary breast cancer. Breast Cancer Res Treat. 2015;149:761\u20135.","journal-title":"Breast Cancer Res Treat"},{"key":"61_CR29","doi-asserted-by":"publisher","first-page":"1072e8","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34:1072e8.","journal-title":"J Clin Oncol"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-021-00061-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s43046-021-00061-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-021-00061-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T14:02:49Z","timestamp":1616853769000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-021-00061-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["61"],"URL":"https:\/\/doi.org\/10.1186\/s43046-021-00061-9","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,8]]},"assertion":[{"value":"13 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There is a discrepancy in the Ethics approval and consent to participate statement provided in the Declarations section and in the Methods section of this article. Ethics approval and consent to participate statement has been modified.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Board of the National Cancer Institute, Egypt. IRB No: IRB00004025, FWA No: FWA00007284, Organization No: IORG0003381.No consent to participate was required as the study is auditing practice retrospectively.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}